Multiple Sclerosis Drugs Market: By Product Type, By Administration, & By Geography - Forecast 2016-2021

  • ID: 3974020
  • Report
  • 144 pages
  • IndustryARC
1 of 3
Multiple sclerosis (MS) is a nervous system disease which affects spinal cord and the brain. MS damages the myelin sheath. Myelin sheath is a term which exemplifies that material which surrounds and protects human nerve cells. Globally, high Unmet need of drugs for treatment of the disease, increased research in the field of MS to develop innovative therapies are the prime growth drivers of global Musculoskeletal Diseases market. In addition, increase in adoption of Multiple Sclerosis Drugs in emerging economies such as China, India and others, will create new opportunities for global Multiple Sclerosis Drugs market. However, patent expiry of major drugs and advancement in biomedical science are the key restraints for global Musculoskeletal Diseases market.

Geographically North America dominated global Multiple Sclerosis Drugs market, The U.S. represents the largest market for MS drugs followed by Canada in North America. In Europe, France, Germany, Italy, Spain and the U.K. holds major share of MS drugs market. However, Asia is expected to show high growth rates in the next five years in global MS drugs market. Among all the product types, Immunomodulators has the highest market share in global Multiple Sclerosis Drugs market.

This report identifies the global pharmaceutical contract manufacturing market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the market drivers, restraints, growth indicators, challenges, and other key aspects with respect to global pharmaceutical contract manufacturing market.

This report segments global Multiple Sclerosis Drugs market on the basis of product type, administration, and regional market as follows:

Multiple Sclerosis Drugs Market, By Product Type: Product Type (Immunomodulators, Immunosuppressant, Others) and Others
Multiple Sclerosis Drugs Market, By Administration (Inject able, Infused, Oral and Others
This report has been further segmented into major regions, which include detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region. The major countries considered under the Asia-Pacific region are India, China, South Korea and Japan. The major countries considered under the European region are Germany, U.K., France, Italy, Spain and Russia. The major countries considered under the North American region are United States, Canada and Mexico

This report identifies all the major companies operating in the Multiple Sclerosis Drugs market. Some of the major companies’ profiles in detail are as follows:

Bayer
GlaxoSmithKline
Teva Pharmaceutical
Novartis
Merck Serono
Please Note: The report is to be delivered in 1-2 working days after an order is placed.
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1. Multiple Sclerosis Drugs Market – Market Overview

2. Executive Summary

3. Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.3. Product Benchmarking
3.4. End User Profiling
3.5. Top 5 Financials Analysis

4. Multiple Sclerosis Drugs Market– Market Forces
4.1. Drivers
4.1.1. High Unmet need of drugs for treatment of the disease
4.1.2. increased research in the field of MS to develop innovative therapies
4.2. Restraints
4.2.1. Patent expiry of major drugs
4.2.2. Advancement in biomedical science
4.3. Opportunities
4.3.1. Emerging economies
4.3.2. Increase in adoption of Multiple Sclerosis Drugs
4.4. Challenges
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Degree of Competition

5. Multiple Sclerosis Drugs Market– Strategic Analysis
5.1. Value Chain Analysis
5.2. Pricing Analysis
5.3. Opportunities Analysis
5.4. Product/Market Life Cycle Analysis
5.5. Suppliers and Distributors

6. Multiple Sclerosis Drugs Market, By Product Type
6.1. Immunomodulators
6.2. Immunosuppressant
6.3. Others

7. Multiple Sclerosis Drugs Market, By Administration
7.1. Injectable
7.2. Infused
7.3. Oral
7.4. Others

8. Multiple Sclerosis Drugs Market, By Geography
8.1. Europe
8.1.1. Germany
8.1.2. France
8.1.3. Italy
8.1.4. Spain
8.1.5. Russia
8.1.6. U.K.
8.1.7. Rest of Europe
8.2. Asia Pacific
8.2.1. China
8.2.2. India
8.2.3. Japan
8.2.4. South Korea
8.2.5. Rest of Asia-Pacific
8.3. North America
8.3.1. U.S.
8.3.2. Canada
8.3.3. Mexico
8.4. Rest of the World (RoW)
8.4.1. Brazil
8.4.2. Rest of RoW

9. Multiple Sclerosis Drugs – Market Entropy
9.1. Expansion
9.2. Technological Developments
9.3. Merger & Acquisitions, and Joint Ventures
9.4. Supply- Contract

10. Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)
10.1. Bayer
10.2. GlaxoSmithKline
10.3. Teva Pharmaceutical
10.4. Novartis
10.5. Merck Serono
10.6. Sanofi
10.7. Pfizer
10.8. Abbvie
10.9. Biogen Idec
10.10. AB Science
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"

11. Appendix
11.1. Abbreviations
11.2. Sources
11.3. Research Methodology
11.4. Bibliography
11.5. Compilation of Expert Insights
11.6. Disclaimer
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll